Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (ASX:RCE) completes dosing of the first male and female subjects in its UTI/urosepsis clinical trial at the highest concentration of R327
- The dosing lasts 15 minutes at 3000mg and was approved by an independent safety committee unanimously to run faster
- The company recruited a full cohort and is dosing the last remaining patients in the coming days
- RCE shares are up 2.33 per cent, trading at 44 cents at 12:37 pm AEDT
Recce Pharmaceuticals (ASX:RCE) has completed dosing the first male and female subjects in its UTI clinical trial at the highest concentration of Recce 327 (R327).
The dosing was completed in 15-minute intervals at 3000 milligrams within Recce’s phase I/II UTI/urosepsis clinical trial, and it has been approved by an independent safety committee unanimously to be administered at a faster interval.
“To be dosing at twice the speed of the last cohort to 3000mg over 15 minutes via intravenous administration is a testament to the safety and tolerability profile of R327, another important clinical milestone for the company,” RCE CEO James Graham said.
The company recruited a full cohort and is dosing the last remaining patients in the coming days.
RCE shares were up 2.33 per cent, trading at 44 cents at 12:37 pm AEDT.
